This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Years of investment in digital, cloud and security strategy has helped Accenture evolve as a trusted and viable consulting services provider. It is currently the world’s top consultancy firm by revenues that increased 5% in 2019 with a contribution of 56% from consulting services.
Waste Connections (WCN) Acquires American Disposal Services
by Zacks Equity Research
The acquisition of American Disposal Services is expected to expand Waste Connections' (WCN) geographic footprint and boost the top line.
Why the Earnings Surprise Streak Could Continue for Accenture (ACN)
by Zacks Equity Research
Accenture (ACN) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Here's Why You Should Hold WEX Stock in Your Portfolio Now
by Zacks Equity Research
WEX continues to benefit from solid organic growth and strategic acquisitions.
Adobe Systems (ADBE) to Report Q4 Earnings: What's in Store?
by Zacks Equity Research
Adobe's (ADBE) fiscal fourth-quarter results are likely to be driven by strength in Creative Cloud.
The Zacks Analyst Blog Highlights: Verizon, Eli Lilly, Accenture, VMware and Schwab
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Verizon, Eli Lilly, Accenture, VMware and Schwab
Top Stock Reports for Verizon, Eli Lilly & Accenture
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including Verizon (VZ), Eli Lilly (LLY) and Accenture (ACN).
III or ACN: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
III vs. ACN: Which Stock Is the Better Value Option?
Accenture Completes Kolle Rebbe Buyout, Focuses on Germany
by Zacks Equity Research
The Kolle Rebbe acquisition to boost Accenture's (ACN) Communications, Media & Technology segment.
The Zacks Analyst Blog Highlights: Johnson & Johnson, Thermo Fisher, Goldman Sachs, Oracle and Accenture
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Johnson & Johnson, Thermo Fisher, Goldman Sachs, Oracle and Accenture
Accenture Opens Innovation Hub in Canada, 800 Jobs in Focus
by Zacks Equity Research
The innovation hub is expected to complement Accenture's (ACN) robust growth in North America.
Top Analyst Reports for Johnson & Johnson, Thermo Fisher & Goldman Sachs
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including Johnson & Johnson (JNJ), Thermo Fisher (TMO) and Goldman Sachs (GS).
Accenture Brings Open Partner Ecosystem for Drug Discovery
by Zacks Equity Research
The ecosystem backed by cloud-based informatics research platform is likely to drive Accenture's (ACN) Products Segment.
IT vs ACN: Which Consulting Services Stock is Better Placed?
by Zacks Equity Research
A faster share price rally led to rich valuation for Gartner (IT) compared with Accenture (ACN).
Accenture (ACN) Opens Innovation Hub, Aims to Add 300 Jobs
by Zacks Equity Research
Accenture (ACN) strengthens North American footprint with innovation hub in Seattle.
Accenture Completes Kaplan Buyout, Boosts Nordics Presence
by Zacks Equity Research
The acquisition of Kaplan is a part of Accenture (ACN) Interactive's bid to boost Nordics presence.
Genpact (G) Q3 Earnings Surpass Estimates, Revenues Miss
by Zacks Equity Research
Genpact's (G) third-quarter 2018 earnings and revenues improve on a year-over-year basis.
Accenture (ACN) Gains But Lags Market: What You Should Know
by Zacks Equity Research
In the latest trading session, Accenture (ACN) closed at $158.58, marking a +0.61% move from the previous day.
Why Is Accenture (ACN) Down 9.2% Since Last Earnings Report?
by Zacks Equity Research
Accenture (ACN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Here's How IQVIA Will Benefit From Genomics England Allaince
by Zacks Equity Research
IQVIA's (IQV) partnership with Genomics England is expected to boost the Technology & Analytics Solutions segment.
Robots Might Soon be Hiring You: 3 Robotics Stocks in Focus
by Zacks Equity Research
The widespread use of automation in recruitment opens up possibilities of AI-powered robots hiring candidates in the near future. Given the continued improvement in the AI market, robotics stocks should be on your watch list.
Accenture (ACN) Builds Healthcare Solution on SAP Cloud
by Zacks Equity Research
The new solution from Accenture (ACN) is aimed at encouraging patients to overcome phantom limb pain.
Accenture (ACN) Q4 Earnings & Revenues Surpass Estimates
by Zacks Equity Research
Accenture (ACN) fourth-quarter fiscal 2018 earnings and revenues improve on a year-over-year basis.
Accenture (ACN) Surpasses Q4 Earnings and Revenue Estimates
by Zacks Equity Research
Accenture (ACN) delivered earnings and revenue surprises of 1.94% and 1.74%, respectively, for the quarter ended August 2018. Do the numbers hold clues to what lies ahead for the stock?
Accenture Boosts Intelligent Patient Platform with A.I. Bots
by Zacks Equity Research
Accenture's (ACN) Health & Public Services and Products segments are likely to get a boost with the inclusion of Ella and Ethan in its Intelligent Patient Platform.
Accenture (ACN) to Report Q4 Earnings: What's in Store?
by Zacks Equity Research
Revenue strength across all the segments, solid bookings and strong operating performance are likely to boost Accenture's (ACN) fourth-quarter fiscal 2018 results.